EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex Bio-Technology (1061.HK) 2026 Interim Results at a glance

2026.08.05

H1 2026 Results Announcement: Regulatory Headwinds Drag Down, Revenue by 10.5% to HK$784.7 million and Profit by 32.2% to HK$110.7 million, Interim Dividend HK$0.05

2026.08.05

Essex Bio-Technology enters Strategic Collaboration Framework Agreement with Gunze Medical to further Commercial Access and to advance Research in Regenerative Medicine and Wound Care

2026.07.23

Date

Title

2018-08-10

Group Turnover and Profit in the First Half of 2018 Increased 28.3%

2018-07-24

Essex Bio-Technology Investing in Chengdu Shanggong Medical Technology Co.,Ltd., A Data Analytics Company for Diabetic Retinopathy Diagnosis

2018-07-18

Essex Bio-Technology Enters into Global Co-Development Agreement with Mitotech to Fund Phase 3 Clinical Trial in U.S. FDA of a First-In-Class Drug for Dry Eye Disease

2018-04-12

Zhuhai Essex Bio-Pharmaceutical Obtained a GMP Certificate for Preservative-Free Single-Dose Tobramycin Eye Drops

2018-04-10

Essex Bio-Technology appoints Dr. Xue Qi as Chief Scientific Officer for its R&D Centre in USA

2018-03-16

Group Profit Recorded Growth of 22.8% in 2017

2018-03-06

Change of Company Logo Represents a Transformation for Essex Bio-Technology Pioneering Global Regenerative Science & Technology

2018-02-26

Essex Bio-Technology announces investment in MeiraGTx, a biotech company developing novel gene therapy treatments

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT